CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education

Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com

PLASMA 2027: Advancing Clinical Excellence in Multiple Myeloma

PLASMA 2027 is a specialized masterclass focusing on the latest scientific advances and clinical applications in the treatment and management of multiple myeloma.

2 daysProgram duration

Course Overview

PLASMA 2027 is a specialized masterclass focusing on the latest scientific advances and clinical applications in the treatment and management of multiple myeloma.

The PLASMA Masterclass is a premier, CME-accredited regional scientific congress designed specifically to translate the latest international breakthroughs in plasma cell dyscrasias and hematologic oncology directly into practical, real-world clinical decision-making across the Gulf region. Centered on advancing clinical excellence in the treatment and comprehensive management of multiple myeloma, AL amyloidosis, and related plasma cell disorders, this high-level educational forum convenes consultant hematologists, medical oncologists, hematopoietic stem cell transplantation (HSCT) specialists, clinical pharmacologists, specialized laboratory pathologists, and multidisciplinary oncology nursing teams. As the therapeutic landscape for plasma cell malignancies evolves at an unprecedented pace, the masterclass serves as an indispensable bridge between cutting-edge global clinical trial data, regulatory approvals, and everyday bedside protocols tailored to the unique clinical demographics of regional healthcare systems. The masterclass curriculum delivers an intensive, high-yield examination of the entire continuum of multiple myeloma care, spanning early risk stratification, frontline management, and long-term disease monitoring. Key instructional modules focus on the practical implementation of novel daratumumab-based quadruplet induction regimens, optimal timing for autologous stem cell transplantation (ASCT), risk-adapted consolidation and maintenance paradigms, and the evolving clinical role of minimal residual disease (MRD) negativity assessment in guiding treatment cessation or escalation. Special emphasis is dedicated to navigating the complex landscape of relapsed/refractory multiple myeloma (RRMM), providing attending clinicians with evidence-based decision frameworks for deploying next-generation targeted agents, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies. Furthermore, dedicated modules address critical supportive care strategies, including bisphosphonate therapy for bone disease, renal impairment management, infection prophylaxis during intensive immunotherapy, and proactive adverse-event management protocols to optimize treatment adherence and patient quality of life. Through a dynamic mix of keynote lectures delivered by global key opinion leaders, interactive "Meet the Expert" small-group breakout discussions, and challenging real-world case debates, the PLASMA Masterclass fosters an environment of rigorous peer-to-peer exchange and regional consensus building. Attending delegates analyze challenging clinical scenarios—such as managing high-risk cytogenetics, frail or elderly populations, and multi-class refractory disease—to refine their diagnostic precision and therapeutic selection. By bringing together international pioneer researchers alongside prominent regional clinical leaders, the meeting equips multidisciplinary oncology teams with actionable, evidence-based management algorithms and updated clinical tools necessary to standardize care pathways, optimize patient safety, and significantly extend long-term survival outcomes for patients with plasma cell disorders across the region.

What you'll learn

Understand the latest scientific advances in the biology and pathogenesis of multiple myeloma.
Evaluate emerging therapeutic options, including CAR T-cell therapy and bispecific antibodies.
Apply evidence-based guidelines to optimize clinical care and treatment sequencing for newly diagnosed and relapsed patients.
Identify strategies to manage treatment-related toxicities and improve patient quality of life.
Analyze recent clinical trial data to inform and enhance clinical decision-making in multiple myeloma management.

Course Content

3 Modules • Detailed Clinical Curriculum
  • CAR T-cell Therapy

    Exploring the latest advancements and clinical outcomes of CAR T-cell therapies in myeloma patients.

  • Bispecific Antibodies

    Understanding the role and efficacy of bispecific antibodies in relapsed and refractory settings.

  • Novel Targeted Agents

    Reviewing new drug classes and targeted therapies currently in clinical trials.

  • Genomic Profiling

    Utilizing genomic data to risk-stratify patients and personalize treatment plans.

  • Minimal Residual Disease (MRD)

    The prognostic value of MRD monitoring and its impact on treatment decisions.

  • Frontline Treatment Paradigms

    Optimizing induction, consolidation, and maintenance therapies for newly diagnosed patients.

  • Managing Relapsed/Refractory Disease

    Evidence-based sequencing of therapies for patients with relapsed or refractory multiple myeloma.

  • Supportive Care

    Strategies for managing treatment-related toxicities and improving patient quality of life.

Key Features

Expert-led sessions by renowned international and regional faculty In-depth exploration of the latest scientific advances in multiple myeloma Practical applications of emerging therapies in real-world clinical care Networking opportunities with leading hematologists and oncologists Interactive discussions on complex clinical cases and treatment sequencing
Registration

Course registration

Secure your seat and earn full credit eligibility with encrypted checkout.

Total due
Free

Secure payment processing & PCI-aligned flow

Organizing Committee

Scientific Committee

Prof. Mohamad Mohty
Prof. Mohamad Mohty
Professor of Hematology, Head of the Clinical Hematology and Cellular Therapy Department

Chairperson

Prof. Mohamad Mohty
Chairperson
FREE
Secure checkout processing
This course includes:

Your registrations

Enter the email you used to register — no account required.

CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education